Zilbrysq - Drug Monograph

Introduction

Zilbrysq (zilucoplan) is a subcutaneously administered macrocyclic peptide inhibitor of complement component C5, approved for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. It represents the first subcutaneously self-administered complement C5 inhibitor, offering an alternative to intravenous terminal complement blockade (eculizumab, ravulizumab). Its clinical use is contingent upon appropriate vaccination against encapsulated bacteria, particularly Neisseria meningitidis, due to its mechanism-related infection risk.

Drug Class and Overview

• Class: Complement inhibitors; macrocyclic peptide C5 inhibitors.
• Related agents: Eculizumab and ravulizumab (recombinant humanized monoclonal IgG antibodies targeting C5). Zilucoplan is structurally distinct—a small synthetic cyclic peptide (~3.5 kDa) that binds C5 with high affinity and sterically blocks cleavage by the C5 convertase.
• Distinguishing features:
• Once-daily subcutaneous self-administration (versus weight-based intravenous infusion for eculizumab/ravulizumab).
• No monoclonal antibody backbone; therefore, no expected risk of infusion reactions typical of IV antibodies and no dependence on neonatal Fc receptor recycling.
• Pre-filled syringe formulation for outpatient use.

Mechanism of Action

Zilucoplan binds to complement component C5 and prevents its cleavage by C5 convertase into C5a (anaphylatoxin) and C5b (initiator of the terminal complement cascade). By blocking C5 cleavage, the drug inhibits formation of the terminal complement complex (C5b-9, the membrane attack complex) and C5a-mediated pro-inflammatory signaling. In AChR-positive myasthenia gravis, complement-mediated damage to the postsynaptic neuromuscular junction is a key driver of fatigable weakness; interrupting this pathway reduces acetylcholine receptor destruction and improves neuromuscular transmission.

Indications

• Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
• Limitation of use: not indicated for use in patients with isolated ocular MG.

Dosage and Administration

• Route: Subcutaneous injection (abdomen, thighs, or upper arms); rotate injection sites.
• Recommended adult dosing (FDA-approved weight-tiered regimen):
• <56 kg: 16.6 mg subcutaneously once daily.
• 56 to <77 kg: 23 mg subcutaneously once daily.
• ≥77 kg: 32.4 mg subcutaneously once daily.
• Initiation: Patients should be vaccinated against N. meningitidis (serogroups A, C, W, Y, and B) at least 2 weeks before starting therapy, unless the urgency of treatment outweighs the risk of delayed vaccination; in that case, prophylactic antibiotics are typically administered for at least 2 weeks after vaccination.
• Renal/hepatic impairment: No dosage adjustment is expected based on population pharmacokinetic analyses; zilucoplan is a peptide and is not eliminated via CYP-mediated hepatic metabolism.
• Pediatric patients: Safety and efficacy have not been established.
• Geriatric patients: Limited data; use with attention to infection risk.
• Pregnancy/Lactation: Insufficient human data; use only if the potential benefit justifies the potential risk to the fetus. A risk to breastfed infants cannot be excluded.

Pharmacokinetics

• Absorption: Following subcutaneous administration, peak plasma concentrations are reached in approximately 3–6 hours; absolute bioavailability is high (consistent with subcutaneous peptides).
• Distribution: Primarily confined to plasma; volume of distribution is low. Plasma protein binding is modest (predominantly to serum albumin).
• Metabolism: Catabolized via proteolytic degradation to small peptides and individual amino acids. Not a substrate of CYP450 enzymes; minimal hepatic metabolism.
• Elimination: Excreted as peptide fragments and amino acids; renal elimination of intact peptide is negligible.
• Half-life: Approximately 14–18 days (consistent with the maintenance dosing interval not requiring additional loading complexity at steady state).

Contraindications

• Unresolved serious infection caused by Neisseria meningitidis.
• Initiation in patients who are not up-to-date with recommended meningococcal vaccination, unless the risk of delaying therapy is judged to outweigh the risk of meningococcal infection (with appropriate bridging antibiotic prophylaxis).

Warnings and Precautions

• Serious meningococcal infections: Like other terminal complement inhibitors, zilucoplan substantially increases susceptibility to N. meningitidis. Patients must be vaccinated (MenACWY and MenB) prior to initiation. Counsel patients to seek immediate medical attention for any symptoms suggestive of meningitis or sepsis (fever, headache with neck stiffness, photophobia, rash, altered mental status).
• Other serious infections: Increased risk of infections caused by encapsulated organisms (e.g., Streptococcus pneumoniae, Haemophilus influenzae). Consider additional vaccinations per ACIP guidance.
• Injection site reactions: Erythema, pruritus, pain, swelling, and induration are common; rotate sites and observe technique.
• Drug-induced immune complex disease / hypersensitivity: Monitor for systemic hypersensitivity reactions.
• Discontinuation risk: Monitor for disease worsening after stopping therapy; rebound has not been definitively established but gradual discontinuation with attention to MG symptom control is prudent.

Drug Interactions

• CYP-mediated interactions: None expected—zilucoplan is not metabolized by CYP450 enzymes and does not induce or inhibit CYP isoforms.
• Vaccines: Live vaccines may have reduced safety/efficacy in patients on complement inhibitors; defer non-essential live vaccines during treatment where possible.
• Other complement inhibitors: Concomitant use with eculizumab or ravulizumab is not recommended.
• Immunosuppressants: Concomitant use with azathioprine, mycophenolate, corticosteroids, or other immunosuppressants commonly used in MG may compound infection risk; monitor accordingly.

Adverse Effects

• Very common (>10%): Injection site reactions (erythema, bruising, pruritus, pain, swelling), upper respiratory tract infections.
• Common (1–10%): Diarrhea, nausea, headache, fatigue, urinary tract infection, abdominal pain.
• Serious/rare: Meningococcal sepsis or meningitis, other bacterial sepsis, hypersensitivity reactions, severe injection site reactions.

Monitoring Parameters

• Vaccination status: Confirm completion of meningococcal (MenACWY and MenB) and other age-appropriate vaccinations prior to initiation.
• Infection surveillance: Educate patients and monitor for early signs of meningococcal or other serious infection at every visit; consider an emergency medical card.
• Clinical efficacy: Use standardized MG assessment tools (MG-ADL, MG-QOL15, MG Composite, Quantitative MG score) at baseline and periodically after starting therapy.
• Laboratory monitoring: No specific routine labs are mandated by the label; monitor as clinically indicated (CBC, signs of infection).
• Injection site inspection: Examine sites at follow-up visits; review injection technique.

Patient Education

• Use the pre-filled syringe exactly as instructed; rotate injection sites and avoid tender, bruised, scarred, or hard areas.
• Recognize and seek immediate medical attention for symptoms of meningococcal infection: fever, severe headache, stiff neck, sensitivity to light, confusion, rash, muscle pain.
• Carry an alert card identifying you as a complement inhibitor recipient.
• Keep all vaccinations current; discuss any planned immunizations with your clinician.
• Report worsening muscle weakness, swallowing or breathing difficulty, or any new infections.
• Do not stop the medication abruptly without discussing with your neurologist.
• Women of childbearing potential should discuss pregnancy and breastfeeding plans with their clinician.

Clinical Pearls

• Zilucoplan is the first self-administered subcutaneously dosed C5 inhibitor; patients receive it as a daily injection rather than an IV infusion in a clinic.
• Because zilucoplan blocks cleavage of C5 proximally to C5a and C5b, it does not preserve the function of the proximal complement pathways (C1–C4)—this matters for infection risk counseling.
• AChR-antibody positive status is a defining eligibility criterion; the pivotal RAISE trial did not establish benefit in AChR-negative patients.
• Adherence to meningococcal vaccination (MenACWY and MenB) is a non-negotiable step before initiation—incorporate this into a clinic workflow to avoid delayed starts.
• Unlike monoclonal antibody C5 inhibitors, zilucoplan is dosed daily with weight-based subcutaneous fixed dosing, simplifying regimen planning but requiring daily patient action.
• In patients who switch from intravenous C5 inhibitors, be aware of differing pharmacokinetics—transition planning should incorporate expected time to washout of the prior agent.

References

1. UCB, Inc. Zilbrysq (zilucoplan) Prescribing Information. U.S. Food and Drug Administration; 2023.
2. Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology. 2023;22(5):395-406.
3. U.S. Food and Drug Administration. FDA Approves New Treatment for Adults with Generalized Myasthenia Gravis (News Release, September 29, 2023).
4. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122.
5. Sanders DB, Wolfe GI, Benatar M, et al. International Consensus Guidance for Management of Myasthenia Gravis – Executive Summary. Neurology. 2016;87(4):419-425.
6. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Recommendations for Meningococcal Vaccination. CDC; current edition.
7. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurologic Clinics. 2018;36(2):311-337.
8. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. Journal of Clinical Investigation. 2006;116(11):2843-2854.
9. Goodnow CK, Tao M, Hey-Hadavi J, et al. Zilucoplan, a subcutaneously self-administered macrocyclic peptide inhibitor of complement C5, in gMG. Neurology: Neuroimmunology & Neuroinflammation (RAISE trial supporting analyses). 2024.
10. Lexicomp Online. Zilucoplan. Wolters Kluwer; updated periodically.
11. Burns TM. Treatment of Myasthenia Gravis with Complement Inhibitors. Neurotherapeutics. 2024.
12. Dalakas MC. Progress in the therapy of myasthenia gravis with complement inhibitors. Nature Reviews Neurology. 2024.